Business
Watertown Biotech Company Being Investigated for Breach of Fiduciary Duties
|
The following piece came from Shareholders Foundation:
An investigation was announced over possible breaches of fiduciary duties by certain directors at SQZ Biotechnologies Company. Investors who purchased shares of SQZ Biotechnologies Company (NYSE: SQZ) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779-1554. The investigation by a law firm concerns whether certain SQZ Biotechnologies directors breached their fiduciary duties and caused damage to the company and its shareholders.Watertown, MA based SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. SQZ Biotechnologies Company reported that its annual Total Revenue rose from $20.99 million in 2020 to $27.09 million in 2021, and that its Net Loss increased from $50.52 million in 2020 to $68.74 million in 2021. On or around October 29, 2022, SQZ Biotechnologies Company conducted its initial public offering (“IPO”), selling 4,411,765 shares priced at $16.00 per share.